Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback

  • FY net sales (0% cc[2]) in line with prior year due to strong Growth Products performance
    • Cosentyx (USD 1.1 billion) reached blockbuster status
    • Entresto (USD 170 million) continued to grow steadily, following positive treatment guidelines in US and Europe and ongoing US field force expansion
    • Gilenya (USD 3.1 billion, +14% cc) delivered double-digit growth
    • Oncology grew 12% (cc) excluding Gleevec/Glivec, driven by new assets and Jakavi
    • Sandoz Biopharmaceuticals[1] grew 31% (cc) to reach USD 1.0 billion …
/by